The aim of the deal is ‘to accelerate the industry’s understanding of high quality, cost-efficient biosimilars and advance the adoption of these complex drugs’. Oncobiologics has also entered into an agreement with Premier’s real-world research and analytics division, Premier Research Services, to leverage the scale, expertise, and integrated quality and cost information across Premier’s alliance of approximately 3,600 US hospitals. Premier and Oncobiologics will also conduct analyses to advise decision-making at Oncobiologics regarding market dynamics.

Oncobiologics is currently developing a portfolio of eight monoclonal antibody biosimilars. Its most advanced biosimilars are ONS-3010 (adalimumab) and ONS-1045 (bevacizumab), both of which have successfully completed phase I trials [1]. The company expects to start phase III trials for these biosimilars during 2016. Other biosimilar candidates in Oncobiologics pipeline include biosimilar versions of Erbitux (cetuximab), Herceptin (trastuzumab) and Rituxan (rituximab) [2].

According to Premier, biological and other specialty drugs are projected to account for 50% of total US drug expenditures by 2018 even though just 1–3% of the population uses these therapies.

Permier and Oncobiologics also say that they will work closely to inform providers, prescribers and the public sector on complexities involved in bringing biosimilars to market.

Related article
Oncobiologics and IPCA create biosimilars alliance

Source: Premier

References
1. GaBI Online - Generics and Biosimilars Initiative. Adalimumab biosimilar meets primary endpoints in first clinical study [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2016 Mar 25]. Available from: www.gabionline.net/Biosimilars/Research/Adalimumab-biosimilar-meets-primary-endpoints-in-phase-I-study
2. GaBI Online - Generics and Biosimilars Initiative. Oncobiologics and Viropro make biosimilar deal [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2016 Mar 25]. Available from: www.gabionline.net/Biosimilars/News/Oncobiologics-and-Viropro-make-biosimilar-deal

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2016 Pro PharmaCommunications International. All Rights Reserved.